-
Featured
Improving the Safety of Vena Caval Thrombectomy in Kidney Cancer with Tumor Thrombus Team Approach
Complete removal of a tumor thrombus resulting from venous tumor invasion is essential for eliminating the cancer in patients with advanced renal cell carcinoma (RCC). A multispecialty tumor thrombus team within an integrated practice can improve the safety of this intricate and extensive procedure.
-
Featured
Benefits of Cytoreductive Nephrectomy with Targeted Cancer Therapy for Metastatic Renal Cell Cancer
Since the advent of targeted cancer therapies in the mid-2000s, there has been a dramatic reduction in cytoreductive nephrectomies. Dr. Michael Blute of Massachusetts General Hospital states that the reduction is concerning, since cytoreductive nephrectomy can provide a strong survival advantage to patients with metastatic disease.
-
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy
Massachusetts General Hospital researchers observed low rates of acute kidney injury (AKI) after tisagenlecleucel therapy but detected the first case of AKI in a patient with macrophage activation syndrome/hemophagocytic lymphohistiocytosis triggered by the therapy.
Kidney Cancer contributors
-
Chin-Lee Wu, MD, PhD
Associate Pathologist, Massachusetts General Hospital and Mass General Cancer Center, Associate Professor of Pathology, Harvard Medical School, Director, Genitourinary Pathology Services
Recent Article
Review: Updates in Histologic Grading of Urologic Neoplasms -
-
Michael L. Blute, MD
Chief, Department of Urology, Walter S. Kerr, Jr., Professor of Surgery, Harvard Medical School
Recent Article
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
